Cargando…
Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
Evidence-based prescribing requires taking into consideration the many aspects of optimal drug administration (e.g., dosage, comorbidities, co-administered drugs, etc.). A key issue is the administration of drugs for acute disorders that may potentially interfere with previously prescribed long-term...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457919/ https://www.ncbi.nlm.nih.gov/pubmed/37624085 http://dx.doi.org/10.3390/pharmacy11040130 |
_version_ | 1785097040099803136 |
---|---|
author | Spanakis, Marios Alon-Ellenbogen, Danny Ioannou, Petros Spernovasilis, Nikolaos |
author_facet | Spanakis, Marios Alon-Ellenbogen, Danny Ioannou, Petros Spernovasilis, Nikolaos |
author_sort | Spanakis, Marios |
collection | PubMed |
description | Evidence-based prescribing requires taking into consideration the many aspects of optimal drug administration (e.g., dosage, comorbidities, co-administered drugs, etc.). A key issue is the administration of drugs for acute disorders that may potentially interfere with previously prescribed long-term medications. Initiating an antibiotic for an acute bacterial infection constitutes a common example. Hence, appropriate knowledge and awareness of the potential DDIs of antibiotics would lead to proper adjustments, thus preventing over- or under-treatment. For example, some statins, which are the most prescribed lipid-modifying agent (LMA), can lead to clinically important drug–drug interactions (DDIs) with the concurrent administration of antibiotics, e.g., macrolides. This review discusses the clinically significant DDIs of antibiotics associated with co-administrated lipid-lowering therapy and highlights common cases where regimen modifications may or may not be necessary. |
format | Online Article Text |
id | pubmed-10457919 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104579192023-08-27 Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications Spanakis, Marios Alon-Ellenbogen, Danny Ioannou, Petros Spernovasilis, Nikolaos Pharmacy (Basel) Review Evidence-based prescribing requires taking into consideration the many aspects of optimal drug administration (e.g., dosage, comorbidities, co-administered drugs, etc.). A key issue is the administration of drugs for acute disorders that may potentially interfere with previously prescribed long-term medications. Initiating an antibiotic for an acute bacterial infection constitutes a common example. Hence, appropriate knowledge and awareness of the potential DDIs of antibiotics would lead to proper adjustments, thus preventing over- or under-treatment. For example, some statins, which are the most prescribed lipid-modifying agent (LMA), can lead to clinically important drug–drug interactions (DDIs) with the concurrent administration of antibiotics, e.g., macrolides. This review discusses the clinically significant DDIs of antibiotics associated with co-administrated lipid-lowering therapy and highlights common cases where regimen modifications may or may not be necessary. MDPI 2023-08-19 /pmc/articles/PMC10457919/ /pubmed/37624085 http://dx.doi.org/10.3390/pharmacy11040130 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Spanakis, Marios Alon-Ellenbogen, Danny Ioannou, Petros Spernovasilis, Nikolaos Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications |
title | Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications |
title_full | Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications |
title_fullStr | Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications |
title_full_unstemmed | Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications |
title_short | Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications |
title_sort | antibiotics and lipid-modifying agents: potential drug–drug interactions and their clinical implications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457919/ https://www.ncbi.nlm.nih.gov/pubmed/37624085 http://dx.doi.org/10.3390/pharmacy11040130 |
work_keys_str_mv | AT spanakismarios antibioticsandlipidmodifyingagentspotentialdrugdruginteractionsandtheirclinicalimplications AT alonellenbogendanny antibioticsandlipidmodifyingagentspotentialdrugdruginteractionsandtheirclinicalimplications AT ioannoupetros antibioticsandlipidmodifyingagentspotentialdrugdruginteractionsandtheirclinicalimplications AT spernovasilisnikolaos antibioticsandlipidmodifyingagentspotentialdrugdruginteractionsandtheirclinicalimplications |